

PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/782,596
		Filing Date	February 19, 2006
		First Named Inventor	Chen Liaw
		Art Unit	1646
		Examiner Name	Ruixiang Li
		Attorney Docket Number	AREN11.US12.CON
Sheet	1	of	1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RLi	1	Barker et al., "Constitutively active 5-hydroxytryptamine <sub>2C</sub> receptors reveal novel inverse agonist activity of receptor ligands," <i>Journal of Biological Chemistry</i> (1994) 269(16):11687-11690.	
	2	Blaszczak "Motor deficiency in Parkinson's disease," <i>Acta Neurobiol Exp</i> (1998) 58:79-93.	
	3	Fischman et al., "Rapid detection of Parkinson's disease by SPECT with altropine: a selective ligand for dopamine transporters," <i>Synapse</i> (1998) 29(2):128-141.	
	4	Karpe et al., "The nicotinic acid receptor--a new mechanism for an old drug," <i>The Lancet</i> (2004) 363(9424):1892-1894.	
	5	Leenders et al., "The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease," <i>Arch Neurol</i> (1990) 47(12):1290-1298.	
	6	Montastruc et al., "New directions in the drug treatment of Parkinson's disease," <i>Drugs &amp; Aging</i> (1996) 9(3):169-184.	
	7	Probst et al., "Sequence alignment of the G-protein coupled receptor superfamily," <i>DNA and Cell Biology</i> (1992) 11(1):1-20.	
	8	Ren et al., "Constitutively active mutants of the alpha 2-adrenergic receptor," <i>Journal of Biological Chemistry</i> (1993) 268(22):16483-16487.	
	9	Sonnhammer et al., "A hidden Markov model for predicting transmembrane helices in protein sequences," J. Glasgow et al., eds., <i>Proc. Sixth Int. Conf. on Intelligent Systems for Molecular Biology</i> , pp. 175-182, AAAI Press (1998).	
RLi	10	Zadina et al., "Endomorphins: novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density," <i>Annals New York Academy of Sciences</i> (1999) 897:136-144.	


Examiner Signature	Ruixiang Li	Date Considered	12/15/2006
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**(Use as many sheets as necessary)**

**Complete if Known**

<b>Application Number</b>	10/782,596
<b>Filing Date</b>	February 19, 2004
<b>First Named Inventor</b>	Chen W. Liaw, et al.
<b>Art Unit</b>	1646
<b>Examiner Name</b>	Ruixiang Li
<b>Attorney Docket Number</b>	AREN11 US12 CON

Sheet	1
-------	---

[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
RLi	A12	CA 2 362 906	08-31-2000	Synaptic Pharmaceutical Corp.		
	A13	EP 1 092 727	04-18-2001	Pfizer Ltd.		
	A14	WO 00/22131	04-20-2000	Arena Pharm Inc.		
	A15	WO 00/50562	08-31-2000	Synaptic Pharma Corp.		
	A16	WO 01/32864	05-10-2001	Merck Patent		
X	A17	WO 01/36473	05-25-2001	Upjohn Co.		
RLi	A18	WO 01/42288	06-14-2001	Incyte Genomics Inc.		

**Examiner  
Signature**

ReiXiang hi

Date Considered

12/18/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of 2

**Complete if Known**

Application Number	10/782,596
Filing Date	February 19, 2004
First Named Inventor	Chen W. Liaw, et al.
Art Unit	1646
Examiner Name	Ruixiang Li
Attorney Docket Number	AREN11.US12.CON

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RLi	A19	BROUN, P., ET AL., "Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity of Plant Lipids," <i>Science</i> , 282:1315-1317, (November 13, 1998)	
	A20	FEHMANN, H-C., ET AL., "Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-Dependent Insulin Releasing Polypeptide," <i>Endocrine Reviews</i> , 16(3):390-410, (1995)	
	A21	LEURS, R., ET AL., "Agonist-independent regulation of constitutively active G-protein-coupled receptors," <i>TIBS</i> , 23:418-422, (November, 1998)	
	A22	MURDOCH, C. and FINN, A., "Chemokine receptors and their role in inflammation and infectious diseases," <i>Blood</i> , 95(10):3032-3043, (May 15, 2000)	
	A23	NG, D.H.W., ET AL., "Point Mutation in the Second Phosphatase Domain of CD45 Abrogates Tyrosine Phosphatase Activity," <i>Biochemical and Biophysical Research Communications</i> , 206(1):302-309, (January 5, 1995)	
	A24	PAUWELS, P.J. and WURCH, T., "Review: Amino Acid Domains Involved in Constitutive Activation of G-Protein-Coupled Receptors," <i>Molecular Neurobiology</i> , 17:109-135, (1998)	
	A25	REN, Q., ET AL., "Constitutively Active Mutants of the $\alpha_2$ -Adrenergic Receptor," <i>The Journal of Biological Chemistry</i> , 268(22):16483-16487, (1993)	
	A26	SKOLNICK, J., ET AL., "Structural genomics and its importance for gene function analysis," <i>Nature Biotechnology</i> , 18:283-287, (March, 2000)	
	A27	THORENS, B., "Expression cloning of the pancreatic $\beta$ cell receptor for the gluco-incretin hormone glucagon-like peptide 1," <i>Proc. Natl. Acad. Sci.</i> , 89:8641-8645, (September, 1992)	
	A28	WATSON, S. and ARKINSTALL, S., <i>The G-Protein Linked Receptor Facts Book</i> , pp. 223-230, (1994)	
RLi	A29	Genebank Accession No. AL035423, version AL035423.4 GI:4467309, "Homo sapiens chromosome X clone 2013," accessed by PTO on 4/28/2004, (February 27, 1999)	

Examiner Signature	Ruixiang Li	Date Considered	12/19/2006
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.